Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Infectious Diseases

Haemophilus Influenzae Infections

Last Updated: January 16, 2007
Email to a Colleague
Synonyms and related keywords: Haemophilus Influenzae, H influenzae, H influenzae type b, Hib, Haemophilus flu, Weeks bacillus, influenza bacillus, bacteremia, occult bacteremia, meningitis, cellulitis, pericarditis, epiglottitis, septic arthritis, pneumonia, empyema, otitis media, conjunctivitis, bronchitis, pneumonia, neonatal sepsis, maternal sepsis, endophthalmitis, urinary tract infection, cervical adenitis, glossitis, osteomyelitis, endocarditis, mucosal infections, Haemophilus aegyptius, H aegyptius, Hib conjugate vaccine, Hib meningitis, Hib pneumonia, nonencapsulated H influenzae infections, nontypeable H influenzae

  AUTHOR INFORMATION Section 1 of 10    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Author: Vidya R Devarajan, MD

Editor(s): Wesley W Emmons, MD, FACP, Assistant Professor, Department of Medicine, Thomas Jefferson University; Consulting Staff, Infectious Diseases Section, Department of Internal Medicine, Christiana Care, Newark, DE; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Charles V Sanders, MD, Edgar Hull Professor and Chairman, Department of Internal Medicine, Louisiana State University Health Sciences Center and School of Medicine; Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital; and Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Disclosure


  INTRODUCTION Section 2 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Background: Haemophilus influenzae is a small (1 X 0.3 mm), pleomorphic, gram-negative coccobacillus. It is a nonmotile, non–spore-forming, fastidious, facultative anaerobe. Some strains of H influenzae possess a polysaccharide capsule. All strains are serotyped into 6 different types (a-f) based on their biochemically different capsules.

The most virulent strain is H influenzae type b (Hib), with its polyribosyl ribitol phosphate (PRP) capsule. It accounts for more than 95% of H influenzae invasive diseases in children and half of invasive diseases in adults, including bacteremia, meningitis, cellulitis, epiglottitis, septic arthritis, pneumonia, and empyema. Less common invasive Hib infections include endophthalmitis, urinary tract infection, abscesses, cervical adenitis, glossitis, osteomyelitis, and endocarditis. The other encapsulated strains occasionally cause invasive disease similar to that of Hib. The nonencapsulated, or nontypeable, H influenzae strains cause mucosal infections, including otitis media, conjunctivitis, sinusitis, bronchitis, and pneumonia. Less commonly, these strains cause invasive disease in children but account for half of the invasive infections in adults. The more common invasive Hib infections and the nontypeable H influenzae diseases are discussed in this article.

Hib conjugate vaccine has led to dramatic declines in incidence and prevalence of these diseases. The Hib carriage rate is 2-4% in children aged 2-5 years, at which time children usually become colonized. Hib carriage rates are lowest in adults and infants and highest in preschoolers. Since the advent of conjugate Hib vaccine, the nasopharyngeal carrier rate has decreased (<1% in vaccinated individuals). Only a small percentage of H influenzae carriers develop invasive disease. The frequency of Hib infections in patients with asplenia, splenectomy, sickle cell disease, malignancies, and congenital or acquired immunodeficiencies is higher than in individuals without these conditions. Unvaccinated infants younger than 12 months with a history of invasive disease have a higher risk of recurrence than vaccinated infants.

Pathophysiology: The nomenclature (Haemophilus is Greek for "blood loving") acknowledges the fact that H influenzae requires 2 erythrocyte factors for growth: X (hemin) and V (nicotinamide-adenine-dinucleotide). These factors are released following lysis of red blood cells, thereby allowing growth of this fastidious organism on chocolate agar. H influenzae consists of 8 biotypes; biotype 3 (Haemophilus aegyptius) is associated with Brazilian purpuric fever, and biotype 4 is a neonatal, maternal, and genital pathogen. Humans are the only natural hosts. H influenzae is a common resident of the nasopharyngeal mucosa and, in some instances, of the conjunctivae and genital tract.

Transmission is by direct contact or by inhalation of respiratory tract droplets. Nasopharyngeal colonization of encapsulated H influenzae is uncommon, occurring in 2-5% of children in the prevaccine era and even less after widespread vaccination. The incubation period is not known. A larger bacterial load or the presence of a concomitant viral infection can potentiate the infection. The colonizing bacteria invade the mucosa and enter the bloodstream. The presence of antibodies, complements, and phagocytes determines the clearance of the bacteremia. The antiphagocytic nature of the Hib capsule and the absence of the anticapsular antibody lead to increasing bacterial proliferation. When the bacterial concentration exceeds a critical level, it can disseminate to various sites, including meninges, subcutaneous tissue, joints, pleura, pericardia, and lungs.

Host defenses include the activation of the alternative and classical complement pathways and antibodies to the PRP capsule. The antibody to the Hib capsule plays the primary role in conferring immunity. Newborns have a low risk of infection, likely because of acquired maternal antibodies. When these transplacental antibodies to the PRP antigen wane, infants are at high risk of developing invasive H influenzae disease, and their immune responses are low even after the disease. Therefore, they are at high risk of repeat infections since prior episodes of H influenzae do not confer immunity. By age 5 years, most children have naturally acquired antibodies. The Hib conjugate vaccine induces protection by inducing antibodies against the PRP capsule. The Hib conjugate vaccine does not provide protection against nontypeable strains. Since the widespread use of the Hib conjugate vaccine, nontypeable H influenzae has become more of a pathogen.

The nontypeable H influenzae strains colonize the nasopharynx in up to 80% of individuals. The spread of bacteria by direct extension to the eustachian tubes causes otitis media. Spread to the sinuses leads to sinusitis. Spread down the respiratory tract results in bronchitis and pneumonia. Eustachian tube dysfunction, antecedent viral upper respiratory tract infection (URTI), foreign bodies, and mucosal irritants, including smoking, can promote infection. In patients with underlying chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF), nontypeable H influenzae frequently colonizes the lower respiratory tract and can exacerbate the disease.

Nontypeable H influenzae form biofilm in vitro and ex vivo and has been implicated in chronic infection such as otitis media, sinusitis, and bronchitis. Nontypeable H influenzae biofilm formation was found in patients with CF on the apical surface of airway epithelia with decreased antibiotic susceptibility. Studies into the nature of this biofilm structure and proteins will help develop strategies to fight chronic infections. Persons at risk for invasive H influenzae disease include those with asplenia, sickle cell disease, complement deficiencies, Hodgkin disease, congenital or acquired hypogammaglobulinemia, and T-cell immunodeficiency states (eg, persons infected with human immunodeficiency virus [HIV]).

Frequency:

  • In the US: Before a vaccine became available in 1988, the annual attack rate of invasive Hib disease was estimated at 64-129 cases per 100,000 children younger than 5 years. By 2000, the number of cases in children younger than 5 years decreased by more than 99%. With the success of the Hib conjugate vaccine, at least half of invasive H influenzae infections are now caused by the nonencapsulated strains, and Hib meningitis has almost disappeared in the United States and Canada.
  • Internationally: Before vaccines became available, invasive Hib disease was a leading infectious illness among children worldwide. Hib vaccine is routine in the Americas, most of Europe and a few countries in Africa and the Middle East.

    In the 1990s, frequency decreased remarkably, and even developing countries reported a frequency of only 2-3 cases per 100,000 of the population younger than 5 years.

    In Canada, 10 centers reported 485 cases of invasive H influenzae disease in 1985. In 2000, 8 years after Canada implemented their Hib immunization program, their Immunization Monitoring Program Active reported only 4 cases. A report of invasive Hib disease in Canadian children identified 29 cases from 2001-2003. The number of cases progressively decreased over the 3 years, with 16 cases reported in 2001, 10 in 2002, and only 3 cases in 2003. A total of 15 cases of meningitis were reported. Six cases of pneumonia with bacteremia and 4 cases of epiglottitis were reported. Two Hib-related deaths occurred. Twenty of these children were unvaccinated or incompletely vaccinated, and 11 were younger than 6 months. Eight of the 9 children who had completed the vaccination series were immunocompromised or had other predisposing conditions. The report noted that the number of cases in older children was unchanged from previous years and that protection did not decline with age.

    In England and Wales, the Hib vaccine was introduced in 1992, and the number of invasive Hib cases in children and adults dramatically decreased. Some felt that this was because of herd immunity due to interruption of transmission from immunized children to those who were unvaccinated. Since 1998, the number of Hib cases has been rising, and, in 2002, 134 cases occurred in children aged 4 years or younger. The increase in invasive Hib in England and Wales was also seen in persons aged 15 years and older and reached prevaccine levels. This was associated with reduced antibody concentration in the older age group. This reduction in herd immunity may be due to reduced transmission of Hib organisms from persons who were vaccinated to adults who were unimmunized, providing fewer opportunities for boosting of natural immunity.

    In Africa and Asia, routine Hib vaccination is not the standard of care, so Hib remains an important disease pathogen. Although measures have been taken to immunize infants and children against Hib in developing countries, the progress has been relatively slow, partly because of financing for the vaccine, sustainable immunization programs, and the need for data on the burden of invasive Hib disease. In Lambok, Indonesia, from 1998-2002, high incidences of vaccine-preventable Hib meningitis and Hib pneumonia were reported in children younger than 2 years. In a district in Malawi, Africa, the incidence of H influenzae meningitis decreased from 20-40 per 100,000 to zero in 2005 after the vaccine was introduced in 2002.

Mortality/Morbidity:

  • Overall mortality from Hib meningitis is approximately 5%. Morbidity rates from meningitis, however, are high. If subtle neurologic changes are included, as many as 50% of individuals with Hib meningitis have some neurologic sequelae, including partial-to-total sensorineural hearing loss, developmental delay, language delay, behavioral abnormalities, language disorders, impaired vision, mental retardation, motor problems, ataxia, seizures, and hydrocephalus. Approximately 6% of individuals with Hib meningitis experience permanent sensorineural hearing loss. The mortality rate for epiglottitis is 5-10% (because of acute respiratory tract obstruction), and, for neonatal H influenzae disease, 55%.
  • Licensing of the Hib conjugate vaccine led to a substantial decline of Hib disease in the United States. In parts of the world where the vaccine is not in regular use, morbidity and mortality rates of Hib disease remain high.
  • Bacteremia and invasive disease associated with nontypeable H influenzae are rare but have a significant mortality rate.

Race: The frequency of Hib disease is especially high in certain ethnic groups, including African Americans, American Indians (eg, Alaskan Eskimos, Navajo, Apache, Yakima, Athabaskan), and Australian Aborigines. Prior to availability of the Hib vaccine, the incidence of invasive disease was 10% higher in American Indians and Alaskan native children compared with the rest of the United States.

Sex: Hib disease has no sex predilection; however, women are at risk for postpartum sepsis, tubo-ovarian abscess, and chronic salpingitis caused by nontypeable H influenzae that colonize the genital tract.

Age:

  • In general, Hib infections are rare in patients older than 6 years because of the acquisition of secondary immunity; however, immunocompromised individuals remain susceptible.
  • Hib meningitis primarily affects children younger than 2 years, with a peak frequency rate occurring in infants aged 6-9 months. Epiglottitis most commonly occurs in children aged 2-7 years but can also occur in adults. Hib pneumonia typically occurs in children aged 4 months to 4 years. Hib causes septic arthritis and cellulitis in children younger than 2 years; before the conjugate vaccine became available, Hib was the leading cause of arthritis in this age group. Hib septic arthritis manifests in adults as well. Prior to introduction of the Hib vaccine, Hib was the leading cause of occult bacteremia after Streptococcus pneumoniae in children aged 6-36 months. In the vaccine era, Hib occult bacteremia is a rare occurrence. H influenzae otitis media can occur at any age but is most common in children aged 6 months to 6 years.
  • Nontypeable H influenzae causes neonatal sepsis through vertical transmission via the female genital tract, maternal sepsis, and, infrequently, other invasive diseases. It also causes otitis media, sinusitis, bronchitis, and pneumonia in all age groups.


  CLINICAL Section 3 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

History:

  • Meningitis
    • This is the most serious manifestation of H influenzae type b (Hib) infection. Symptoms of antecedent URTI are common. Altered mental status and fever are the most common presenting features. Headache and photophobia are usually present in older children.
    • Symptoms related to other infectious foci (eg, cellulitis, arthritis, pneumonia) are encountered in 10-20% of children. Infants have nonspecific symptoms, including irritability, fever, lethargy, poor feeding, and vomiting.
    • H influenzae accounts for 5-10% cases of adult meningitis, and patients can present with at least one of the classic triad of fever, neck stiffness, and altered mental status.
  • Cellulitis: The buccal and periorbital regions are most commonly involved with associated fever. Orbital cellulitis is infrequent and tends to be a complication of ethmoid or sphenoid sinusitis.
  • Epiglottitis: Patients have histories of fever, sore throat, dysphagia, drooling, and difficulty breathing.
  • Pneumonia: Hib pneumonia is clinically indistinguishable from other bacterial pneumonias except for its insidious onset and a patient history of fever, cough, and purulent sputum production.
  • Pericarditis: Patients with Hib pericarditis present with a history of fever, respiratory distress, and tachycardia.
  • Septic arthritis: Patients note joint pain, swelling, and decreased mobility.
  • Occult bacteremia: Fever, anorexia, and lethargy occur in persons with occult bacteremia.
  • Underlying medical conditions: Symptoms of chronic pulmonary disease, HIV infection (and other immunodeficiency states), alcoholism, pregnancy, and malignancy may predominate in adults with invasive Hib disease.
  • Neonatal infections
    • Neonates with H influenzae disease present within 24 hours of birth; these infections are caused by the nontypeable H influenzae, which colonizes on the maternal genital tract.
    • Premature birth, premature rupture of membranes, low birth weight, and maternal chorioamnionitis are associated with H influenzae disease.
    • Manifestations may be nonspecific and may include those of bacteremia, sepsis, meningitis, pneumonia, respiratory distress, scalp abscess, conjunctivitis, and vesicular eruption.
    • Nontypeable H influenzae is a major cause of pneumonia in infants in developing countries.
  • Nonencapsulated H influenzae infections
    • Nonencapsulated H influenzae commonly causes a variety of mucosal infections, including otitis media and conjunctivitis.
    • S pneumoniae and nonencapsulated H influenzae are the most common causes of otitis media, which manifests in infants as fever and irritability and in older patients as ear pain. Frequently, a history of URTI exists.
    • Nontypeable H influenzae is a major pathogen for conjunctivitis in older children and can cause outbreaks, especially in daycare centers. After S pneumoniae, nontypeable H influenzae is the most common cause of community-acquired bacterial pneumonia in adults. It is common in patients with COPD and HIV disease and leads to an exacerbation of COPD, symptoms of which include low-grade fever, increased cough and sputum production, and dyspnea. Nontypeable H influenzae invasive disease is frequently associated with underlying medical conditions, including prematurity, advanced age, alcoholism, malignancy, CF, asthma, cerebrospinal fluid (CSF) leak, CNS shunts, congenital heart disease, and immunoglobulin deficiency.

Physical:

  • Meningitis
    • Clinical manifestations of Hib meningitis are indistinguishable from other causes of bacterial meningitis.
    • The usual presentation consists of a few days of mild illness followed by ominous deterioration.
    • Altered mental status and fever are the most common findings.

    • Seizures and coma develop as the disease progresses.
    • Children may have few specific signs. Nuchal rigidity is often absent in children younger than 18 months. In infants, the disease course may be fulminant, with death occurring within a few hours.
    • Consider the possibility of subdural effusion, a common complication of Hib meningitis, in a patient who has been treated for 3 days with appropriate antibiotics and has experienced a tense anterior fontanelle, seizures (especially if focal), hemiparesis, or altered CNS function.
  • Cellulitis
    • The clinical features are fever and a raised, indurated, tender area with indistinct margins mostly on the head and neck, particularly the buccal and preseptal areas. This is often caused by contiguous sinus disease. The indurated area may progress to a violaceous hue, although this is not specific to Hib.
    • Orbital cellulitis may also occur and is distinguished from preorbital cellulitis by the presence of proptosis, chemosis, impaired vision, limitation of extraocular movements, and pain with eye movement. A secondary focus of infection, including meningitis, is evident in 10-15% of patients with orbital cellulitis.
  • Epiglottitis: Clinical manifestations in children include a toxic, anxious appearance, progressive respiratory difficulty, and the inability to swallow secretions while sitting in the tripod position (ie, sitting with arms back, trunk leaning forward, neck hyperextended and chin forward in an attempt to open the airway fully).
  • Pneumonia: Hib pneumonia is clinically indistinguishable from other bacterial pneumonias.
  • Pericarditis: The individual is acutely ill with fever and respiratory distress.
  • Septic arthritis
    • Hib septic arthritis affects single large joints (eg, knee, ankle, hip, elbow).
    • Symptoms, usually preceded by a URTI, include decreased range of motion, erythema, and warmth and swelling in affected joints, in addition to fever.

    • In adults, joint involvement can be monoarticular or polyarticular.

    • Extra-articular sites of infection, including those associated with meningitis, pneumonia, cellulitis, and sinusitis, may also be evident.
  • Occult bacteremia: Occult bacteremia is characterized by fever (temperature >39°C) with no obvious focus of infection. About 30-50% of patients have focal infections.
  • Nonencapsulated H influenzae infections
  • These can manifest in various mucosal infections (eg, otitis media, conjunctivitis, sinusitis, bronchitis). An otitis media diagnosis is confirmed based on pneumatic otoscopy. Conjunctivitis is usually bilateral and characterized by conjunctival hyperemia and purulent eye discharge.

  • Nontypeable H influenzae strains can cause postpartum sepsis with endometritis, tuboovarian abscess, and chronic salpingitis.
    • Signs of invasive disease in neonates include sepsis, pneumonia, conjunctivitis, respiratory distress syndrome, scalp abscess, cellulitis, meningitis, congenital vesicular eruption, mastoiditis, and septic arthritis.

Causes:

  • Bacteremia precedes Hib meningitis and other invasive Hib diseases.
    • Direct extension of infection from the sinuses or ears is rare.
    • The magnitude and duration of bacteremia are the primary determinants of CNS invasion, which occurs via the choroid plexus.
    • The magnitude of the CSF bacterial density correlates with the severity of the disease.
    • Morbidity and mortality associated with meningitis result from inflammation, edema, and increased CSF pressure.
    • Brain parenchymal invasion is rare.
  • In epiglottitis, Hib invades the epiglottis and supraglottic tissues, causing cellulitis and swelling that causes the epiglottis to curl posteriorly and inferiorly over the airway, thus obstructing airflow during inspiration but allowing normal expiration. An acute airway obstruction follows.
  • Invasive H influenzae disease in neonates is rare and is caused most often by nontypeable strains.
    • This condition is associated with premature birth, premature rupture of membranes, low birth weight, and maternal chorioamnionitis.
    • Transmission occurs through the maternal genital tract.
    • Nontypeable H influenzae biotype 4 can colonize the genital tract and is a major cause of invasive disease.
  DIFFERENTIALS Section 4 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Bronchitis


Other Problems to be Considered:

Otitis media
Epiglottitis

Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Bibliography

Click for related images.

Related Articles
Bronchitis


Patient Education



  WORKUP Section 5 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Lab Studies:

  • Gram stain: Test results on body fluids from various sites of infection that reveal small, gram-negative, pleomorphic coccobacilli with polymorphonuclear cells are strong evidence of infection.
  • Bacterial culture
    • Detection of the organism in a blood culture or any other body fluid is the most confirmatory method of establishing the diagnosis.
    • Slide agglutination with type-specific antisera is used for serotyping H influenzae.
    • Seventy to 90% of patients with epiglottitis have positive blood culture results. However, to avoid laryngospasm, perform venipuncture and cultures of the inflamed epiglottitis only after the airway has been secured.
  • Immunologic studies
    • Detection of the PRP polysaccharide capsule via countercurrent immunoelectrophoresis, latex particle agglutination, co-agglutination, and enzyme-linked immunosorbent assay is an important adjunct to culturing in establishing a rapid diagnosis.
    • Even if antibiotics were previously administered, the diagnosis can be confirmed based on the detection of the polysaccharide capsule in body fluids, including serum, CSF, urine, and pleural, pericardial, and articular fluid. False-positive results in CSF are rare but occur with serum or urine because of nonspecific agglutination and antigenic cross-reactivity with other bacteria.
  • CSF features
    • In meningitis, the CSF examination demonstrates pleocytosis (mean, 4000-5000 WBC/mL) with a predominance of neutrophils.
    • Decreased CSF glucose levels are encountered in 75% of patients, increased CSF protein and detectable capsular antigen in 90%, and a positive CSF Gram stain result in 80%.
    • Prior antibiotic treatment significantly decreases the H influenzae type b (Hib) concentration in the CSF and decreases the sensitivity of the Gram stain; however, antibiotics do not substantially affect the total CSF blood cell count, differential, chemistries, and presence of the PRP capsule in pretreated patients.
  • Blood cell counts: Perform blood cell counts for anemia, leukocytosis, and thrombocytosis or thrombocytopenia.
  • Acute phase reactants: Elevated erythrocyte sedimentation rates (ESRs) and C-reactive protein levels are characteristically observed in patients with septic arthritis.

Imaging Studies:

  • CT scan
    • In meningitis, a CT scan of the head is not required routinely unless focal neurologic findings are present or clinical response is lacking after 3 days' administration of appropriate antibiotics. In these situations, a head CT scan helps identify subdural effusion.
    • In patients with orbital cellulitis, a CT scan of the head is useful in delineating the extent of the lesion.
  • Chest radiograph
    • Patients with Hib pneumonias tend to have more pleural and pericardial involvement (50% of patients) compared to those with other bacterial pneumonias.
    • Community-acquired pneumonias due to nontypeable H influenzae are characterized by alveolar infiltrates in patchy or lobar distributions.
  • Lateral neck radiograph
    • In epiglottitis, a lateral neck radiograph reveals dilatation of the hypopharynx and a swollen epiglottis (termed the thumbprint sign). In addition, the cervical spine is usually straightened.
    • If epiglottitis is clinically suspected, obtain radiographs only if a functional airway is guaranteed.
  • Echocardiogram: Obtain this when pericarditis is suspected.

Other Tests:

  • In patients with cellulitis, direct aspiration of the soft tissue or aspiration after injecting the subcutaneous tissue with sterile nonbacteriostatic solution can lead to detection of the organisms by Gram stain and culture.

Procedures:

  • Perform a lumbar puncture when meningitis is suspected.
  • The following invasive procedures can be used to obtain appropriate fluid and to establish an etiologic diagnosis:
    • Bronchoscopy
    • Joint, lung, sinus, and soft tissue aspiration
    • Transtracheal aspiration
    • Tympanocentesis
    • Pericardiocentesis
  • In women, obtain tubal cultures by laparoscopy and peritoneal fluid cultures by culdocentesis for nontypeable H influenzae.
  • In patients with epiglottitis, use endotracheal intubation or tracheostomy to secure an airway.
  TREATMENT Section 6 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical Care:

  • Antibiotics and supportive care

    • These are the mainstays of treatment.

    • Initially, invasive and serious H influenzae type b (Hib) infections are best treated with an intravenous third-generation cephalosporin until antibiotic sensitivities become available.

    • The site of infection and the clinical response determine the length of antibiotic treatment.

  • Meningitis

    • Administer parenteral antibiotics (eg, ceftriaxone, ceftazidime, cefotaxime, ampicillin-sulbactam, fluoroquinolones, azithromycin) to patients with uncomplicated meningitis for 7-14 days. Cefotaxime or ceftriaxone are the initial drugs of choice for suspected Hib meningitis.

    • Once the susceptibilities are known, adjust antibiotics accordingly.

    • Do not use ampicillin empirically, since as many as 50% of the isolates are resistant, usually because of plasmid-mediated beta-lactamase production.

    • Cefuroxime is also not recommended because delayed sterilization is more common.

    • Chloramphenicol produces adequate bactericidal blood and CSF levels but is now used infrequently because it requires monitoring of drug levels and can result in dose-dependent (though reversible) bone marrow toxicity (particularly in neonates and patients with liver disease) or an idiosyncratic aplastic anemia.

    • Dexamethasone is an important adjunctive treatment for patients with meningitis who are older than 2 months because it has been shown to decrease the inflammatory response and the rate of hearing loss and other neurological complications. Adjuvant dexamethasone therapy is recommended in children but not in adults with H influenzae meningitis.

    • When steroids are used, they must be administered before or with antibiotics, not after.

    • Treatment also includes ongoing supportive care and management of complications such as shock, inappropriate secretion of antidiuretic hormone syndrome, seizures, subdural empyema, and secondary foci of infection.

    • Small, clinically insignificant subdural effusions are common.

    • In uncomplicated cases, a repeat lumbar puncture is unnecessary to ensure sterility of the CSF.
  • Cellulitis

    • For patients with Hib cellulitis, administer parenteral antibiotics until the patient shows defervescence and the cellulitis subsides. Then, administer appropriate oral antibiotics until the course of therapy, usually 7-10 days, is finished. Empiric therapy for preseptal cellulitis should cover not only Hib but also S pneumoniae, Staphylococcus aureus, and group A beta-hemolytic streptococci. Patients with orbital cellulitis require at least 14 days of parenteral therapy.

    • Surgical drainage may be needed for the underlying sinusitis or for orbital abscesses.
  • Epiglottitis

    • Maintenance of a patent airway via intubation or tracheostomy is the mainstay of treatment for epiglottitis.

    • Administer antimicrobial therapy parenterally once the airway is secured, and continue until the patient can receive oral fluids. The total duration of therapy is 7-10 days.
  • Arthritis

    • So far, no studies have accurately defined the appropriate length of therapy for septic arthritis. However, uncomplicated septic arthritis usually requires systemic antibiotics for at least 7 days.

    • If an appropriate clinical response is obtained, oral therapy for 2-3 weeks may follow. Therapy may continue beyond 3 weeks until the ESR begins to normalize. The ESR may lag behind successful clinical response for weeks; accordingly, the C-reactive protein test may be a more useful laboratory tool because its values tend to normalize more rapidly.
  • Bacteremia and other Hib infections

    • Bacteremia precedes essentially all invasive Hib infection.

    • Approximately 30-50% of children with occult Hib bacteremia (bacteremia without an identifiable cause) develop a focus of infection such as meningitis, cellulitis, or pneumonia. Therefore, reevaluate these children (including through the use of lumbar punctures and chest radiographs) for an infectious focus and obtain repeat blood cultures.

    • Administer parenteral antibiotics for at least 2-5 days, and guide subsequent therapy by the focus of infection. If no focus is identified, substitute oral antibiotics to complete 10 days of therapy. Patients with pericarditis, empyema, endocarditis, endophthalmitis, or osteomyelitis require an extended antibiotic treatment duration of 3-6 weeks.

  • Nonencapsulated H influenzae

    • These organisms rarely cause invasive disease but can cause mucosal infections treatable with oral antibiotics. The first-line antibiotic for otitis media is amoxicillin (80-90 mg/kg/d for 7-10 d) because of its safety and low cost.

    • If the organism produces beta-lactamase or if other treatment fails, treatment with amoxicillin-clavulanate is recommended. Penicillin-allergic individuals may be treated with erythromycin-sulfisoxazole or cefaclor. Cefaclor has weak activity against beta-lactamase–producing bacteria and causes a serum sickness–like illness in 2% of patients. Approximately 25-50% of nontypeable strains produce beta-lactamase and, therefore, are resistant to amoxicillin and ampicillin.

    • Beta-lactamase–producing oral antibiotics with activity against H influenzae include trimethoprim-sulfamethoxazole, cefuroxime axetil, cefixime, clarithromycin, azithromycin, and ciprofloxacin. The duration of therapy is 10 days for otitis media and at least 14 days for sinusitis. Treat Administer topical antibiotics such as sulfacetamide and erythromycin to patients with conjunctivitis.
    • Administer parenteral antibiotics to patients with invasive nontypeable H influenzae.

Surgical Care:

  • Patients with subdural and pleural empyema may require surgical drainage if orbital cellulitis is extensive.
  • Patients with pericarditis require systemic antibiotics and drainage via early pericardectomy or pericardiostomy rather than multiple pericardiocentesis.
  • Patients with septic arthritis of the hip require surgical drainage to avoid avascular necrosis of the femoral head. Repeated aspirations or surgical drain placement may be needed in other infected joints to reduce pressure.

Consultations:

  • Consult an ear, nose, and throat specialist and an anesthesiologist for help in securing difficult airways in all cases of suspected epiglottitis.
  • Consult a neurosurgery specialist for suppurative complications of nervous system involvement.
  • Consult an ophthalmologist for management of orbital cellulitis.
  • Consult an infectious disease specialist for assistance with complicated infections.
  • Consult an orthopedic surgeon for surgical drainage of a joint.

  MEDICATION Section 7 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Initially, patients with invasive and serious H influenzae infections are best treated with an intravenous third-generation cephalosporin.

Drug Category: Antibiotics -- Therapy must be comprehensive and cover all likely pathogens in the context of this clinical setting. Penicillins are useful in management of mucosal infections caused by nonencapsulated H influenzae. As many as 25-50% of isolates produce beta-lactamase; therefore, they are resistant to this class of drugs. Third-generation cephalosporins are highly effective in H influenzae infections. Meropenem or ampicillin and chloramphenicol are alternative regimens.
Drug Name
Cefotaxime (Claforan) -- Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms.
Adult Dose2 g IV q4-6h
Pediatric Dose0-1 week: 50 mg/kg IV q12h
1-4 weeks: 50 mg/kg IV q8h
1 month to 12 years: 100-200 mg/kg IV divided q4-6h
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase levels; coadministration with furosemide and aminoglycosides may increase nephrotoxicity
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections, and promotion of non-susceptible organisms may occur with prolonged use or repeated therapy; has been associated with severe colitis; caution in penicillin-allergic patients; administer slowly because life-threatening arrhythmias have been reported with rapid bolus infusions; toxicities include granulocytopenia, agranulocytosis, elevations in serum creatinine and liver enzymes
Drug Name
Ceftriaxone (Rocephin) -- Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms; arrests bacterial growth by binding to one or more penicillin-binding proteins. Exerts antimicrobial effect by interfering with synthesis of peptidoglycan, a major structural component of bacterial cell wall. Bacteria eventually lyse because of the ongoing activity of cell wall autolytic enzymes while cell wall assembly is arrested. Highly stable in presence of beta-lactamases, both penicillinase and cephalosporinase, of gram-negative and gram-positive bacteria. Approximately 33-67% of dose excreted unchanged in urine, and remainder secreted in bile and, ultimately, in feces as microbiologically inactive compounds. Reversibly binds to human plasma proteins, and binding has been reported to decrease from 95% bound at plasma concentrations <25 mcg/mL to 85% bound at 300 mcg/mL.
Adult DoseMeningitis: 2 g IV q12h
Other serious infections: 1-2 g IV/IM q24h
Pediatric DoseMeningitis: 100 mg/kg IV divided q12h
Other serious infections: 50-75 mg/kg IV divided q12h
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in patients allergic to penicillin; reduce dose in renal insufficiency; may cause cholelithiasis, sludging in gallbladder, and jaundice; discontinue if clinical or sonographic evidence of gallbladder disease is detected; caution in breastfeeding women
Drug Name
Cefuroxime (Ceftin, Zinacef) -- This second-generation cephalosporin maintains gram-positive activity of first-generation cephalosporins; adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and Moraxella catarrhalis. Binds to penicillin-binding proteins and inhibits final transpeptidation step of peptidoglycan synthesis, resulting in cell wall death. It is not recommended for treatment of Hib meningitis but may be used for other Hib infections. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.
Adult Dose250-500 mg PO q12h
750-1500 mg IV q8h
Pediatric Dose20-30 mg/kg/d PO q12h
75-150 mg/kg IV q8h
ContraindicationsDocumented hypersensitivity
InteractionsDisulfiramlike reactions may occur when alcohol is consumed within 72 h after taking cefuroxime; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patients receiving potent diuretics such as loop diuretics; coadministration with aminoglycosides increases nephrotoxic potential
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsReduce dosage by one half if CrCl is 10-30 mL/min and by three fourths if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy
Drug Name
Ampicillin (Marcillin, Omnipen, Polycillin, Principen) -- Broad-spectrum penicillin. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take PO medication.
Adult Dose1-2 g IV q6h
Pediatric Dose200-300 mg/kg IV q6h
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid and disulfiram elevate levels; allopurinol decreases effects and exacerbates ampicillin rash; may decrease effects of oral contraceptives
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction
Drug Name
Amoxicillin (Trimox, Amoxil, Trimox) -- Derivative of ampicillin and has similar antibacterial spectrum, namely certain gram-positive and gram-negative organisms. Superior bioavailability and stability to gastric acid and has broader spectrum of activity than penicillin. Somewhat less active than that of penicillin against pneumococcus. Penicillin-resistant strains also resistant to amoxicillin, but higher doses may be effective. More effective against gram-negative organisms (eg, Neisseria meningitidis, H influenzae) than penicillin. Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.
Adult DoseOtitis media: 250-500 mg PO q8h
Sinusitis: 500-1000 mg PO q8h for 7-10 d
Pediatric DoseOtitis media: 40-90 mg/kg/d PO divided q8h for 7-10 d
ContraindicationsDocumented hypersensitivity
InteractionsReduces efficacy of oral contraceptives
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment
Drug Name
Amoxicillin and clavulanic acid (Augmentin) -- Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Addition of clavulanate inhibits beta-lactamase–producing bacteria. Good alternative antibiotic for patients allergic or intolerant to the macrolide class. Is usually well tolerated and provides good coverage to most infectious agents. Not effective against Mycoplasma and Legionella species. The half-life of oral dosage form is 1-1.3 h. Has good tissue penetration but does not enter CSF. For children >3 months, base dosing protocol on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250 mg chewable-tab (250/62.5), do not use 250-mg tab until child weighs >40 kg. The bid dosing schedule reduces incidence of diarrhea.
Adult Dose500 mg/dose PO q8h for 7-10 d
875 mg/dose PO q12h for 7-10 d
Pediatric Dose<3 months: 125 mg/5mL PO susp based on amoxicillin; 30 mg/kg/d divided bid for 7-10 d
>3 months: if using 200 mg/5 mL or 400 mg/5 mL susp, 45 mg/kg/d PO q12h; if using 125 mg/5 mL or 250 mg/5 mL susp, 40 mg/kg/d PO q8h for 7-10 d
>40 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity; history of cholestatic jaundice or hepatic dysfunction following previous amoxicillin-clavulanate therapy
InteractionsCoadministration with warfarin or heparin increases risk of bleeding; may act synergistically against selected microorganisms when coadministered with aminoglycosides; coadministration with allopurinol may increase incidence of amoxicillin rash; may decrease efficacy of oral contraceptives when administered concomitantly
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsHepatic impairment may occur with prolonged treatment in elderly persons; diarrhea may occur; adjust dose in renal impairment; cross-allergy may occur with other beta-lactams and cephalosporins; do not administer to patients with mononucleosis; caution in hepatic dysfunction
Drug Name
Chloramphenicol (Chloromycetin) -- May be used in patients who are allergic to penicillins and cephalosporins. Binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Active in vitro against a wide variety of bacteria, including gram-positive, gram-negative, aerobic, and anaerobic organisms. Well-absorbed from GI tract and metabolized in the liver, where it is inactivated by conjugation with glucuronic acid and then excreted by the kidneys. Oral form is not available in the United States.
Adult Dose50-100 mg/kg/d PO/IV q6h; not to exceed 4 g/d
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; neonates; liver disease
InteractionsAdministered concurrently with barbiturates, chloramphenicol serum levels may decrease, while barbiturate levels may increase, causing toxicity; manifestations of hypoglycemia may occur with sulfonylureas; rifampin may reduce serum chloramphenicol levels, presumably through hepatic enzyme induction; may increase effects of anticoagulants; may increase serum hydantoin levels, possibly resulting in toxicity; hydantoins may either increase or decrease chloramphenicol levels
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsUse for only indicated infections or as prophylaxis for bacterial infections; serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) can occur; evaluate baseline and perform periodic blood studies approximately every 2 d while in therapy; discontinue upon appearance of reticulocytopenia, leukopenia, thrombocytopenia, anemia, or findings attributable to chloramphenicol; adjust dose in liver or kidney dysfunction; caution in pregnancy at term or during labor because of potential toxic effects on fetus (gray syndrome); monitoring of blood levels is essential, especially in infants; hematologic status should be observed closely for idiosyncratic or dose-related bone marrow suppression
Drug Name
Erythromycin and sulfisoxazole (Eryzole, Pediazole) -- Erythromycin is a macrolide antibiotic with a large spectrum of activity. Erythromycin binds to the 50S ribosomal subunit of the bacteria, which inhibits protein synthesis. Sulfisoxazole expands erythromycin's coverage to include gram-negative bacteria. Sulfisoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Good choice for PO therapy for otitis media. May be used in patients who are allergic to penicillins and cephalosporins.
Adult Dose400 mg q6h PO 1 h ac or 500 mg q12h
<45 kg: 50 mg/kg/d erythromycin and 150 mg/kg/d sulfisoxazole PO 1 h ac divided q6h; not to exceed 2 g erythromycin/d or 6 g sulfisoxazole/d for 10 d
>45 kg: 400 mg erythromycin and 1200 mg sulfisoxazole PO 1 h ac q6h
Pediatric Dose50 mg/kg/d erythromycin and 150 mg/kg/d sulfisoxazole PO divided q6h; not to exceed 2 g erythromycin/d or 6 g sulfisoxazole/d for 10 d
ContraindicationsDocumented hypersensitivity; hepatic impairment; children <2 mo
InteractionsCoadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in liver disease; adverse GI effects common; maintain adequate hydration to prevent renal crystallization of sulfisoxazole
Drug Name
Meropenem (Merrem IV) -- Bactericidal broad-spectrum carbapenem antibiotic that inhibits cell-wall synthesis. Effective against most gram-positive and gram-negative bacteria. Has slightly increased activity against gram-negative species and slightly decreased activity against staphylococci and streptococci compared with imipenem. In contrast to imipenem, indicated for treatment of bacterial meningitis, including pediatric meningitis.
Adult DoseMild-to-moderate infections: 1 g IV q8h
Meningitis: 2 g IV q8h
Pediatric Dose40 mg/kg IV q8h; not to exceed 6 g/d
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may inhibit renal excretion of meropenem, increasing meropenem levels
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsDosage adjustments (adult adjustments)
CrCl (mL/min) 10-50: 0.5-1 g q12h
CrCl <10: 0.5 g/d
HD: As for CrCl <10, with an extra 0.5 g after HD
Pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation of medication
Drug Name
Rifampin (Rifadin) -- Used for chemoprophylaxis in Hib infections.
Adult Dose600 mg/d PO for 4 d
Pediatric Dose20 mg/kg/d PO for 4 d
ContraindicationsDocumented hypersensitivity
InteractionsInduces microsomal enzymes, which may decrease effects of acetaminophen, oral anticoagulants, barbiturates, benzodiazepines, beta-blockers, chloramphenicol, oral contraceptives, corticosteroids, mexiletine, cyclosporine, digitoxin, disopyramide, estrogens, hydantoins, methadone, clofibrate, quinidine, dapsone, tazobactam, sulfonylureas, theophyllines, tocainide, and digoxin; blood pressure may increase with coadministration of enalapril; coadministration with isoniazid or pyrazinamide may result in higher rate of hepatotoxicity than with either agent alone (discontinue one or both agents if alterations in LFTs occur)
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsObtain CBC count and baseline clinical chemistries prior to and throughout therapy; in liver disease, weigh benefits against risk of further liver damage; interruption of therapy and high-dose intermittent therapy are associated with thrombocytopenia that is reversible if therapy is discontinued as soon as purpura occurs; if treatment is continued or resumed after appearance of purpura, cerebral hemorrhage or death may occur
Drug Category: Glucocorticoids -- These agents are used as adjunctive therapy in H influenza meningitis for the anti-inflammatory effects and prevention of sensorineural deafness. Administer before or with antibiotics, not after. Utility of steroids has been demonstrated primarily in nonimmunized children, and its usefulness in adults or vaccinated children is not known.
Drug Name
Dexamethasone (Decadron, Baldex) -- Has many pharmacologic benefits but significant adverse effects. Stabilizes cell and lysosomal membranes, increases surfactant synthesis, increases serum vitamin A concentration, and inhibits prostaglandin and proinflammatory cytokines (eg, TNF-alpha, IL-6, IL-2, and IFN-gamma). The inhibition of chemotactic factors and factors that increase capillary permeability inhibits recruitment of inflammatory cells into affected areas. Suppresses lymphocyte proliferation through direct cytolysis and inhibits mitosis. Breaks down granulocyte aggregates and improves pulmonary microcirculation.
Adverse effects are hyperglycemia, hypertension, weight loss, GI bleeding or perforation synthesis, cerebral palsy, adrenal suppression, and death. Most of the adverse effects of corticosteroids are dose-dependent or duration-dependent.
Readily absorbed via the GI tract and metabolized in the liver. Inactive metabolites are excreted via the kidneys. Lacks salt-retaining property of hydrocortisone.
Patients can be switched from an IV to PO regimen in a 1:1 ratio.
Adult DoseDoes not apply
Pediatric Dose0.6 mg/kg/d IV divided q6h for 4 d
ContraindicationsDocumented hypersensitivity; active bacterial or fungal infection
InteractionsEffects decrease with coadministration of barbiturates, phenytoin, and rifampin; dexamethasone decreases effect of salicylates and vaccines used for immunization
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsIncreases risk of multiple complications, including severe infections; monitor adrenal insufficiency when tapering drug; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications of glucocorticoid use
  FOLLOW-UP Section 8 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Further Inpatient Care:

Further Outpatient Care:

In/Out Patient Meds:

Deterrence/Prevention:

Complications:

Prognosis:

Patient Education:

  MISCELLANEOUS Section 9 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical/Legal Pitfalls:

  • H influenzae type b (Hib) resistance to several antibiotics, including ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, rifampin, and some second-generation cephalosporins, has increased worldwide. When choosing an antibiotic, consider the local antibiotic susceptibility patterns of invasive isolates.
  • The treatment of Hib bacteremia and its invasive disease should include penetration of the blood-brain barrier (since occult CNS disease must be considered in any Hib infection), achievement of bactericidal titers, and an adequate duration of therapy to sterilize primary and potential secondary foci.
  • The nasopharyngeal carriage rate of nontypeable H influenzae is high; therefore, a positive culture result is not helpful and should not be used to confirm a diagnosis of H influenzae disease.
  • If epiglottitis is suspected, securing an airway prior to doing anything that might make the patient more anxious is crucial.

Special Concerns:

  • Recent genetic studies have revealed that the bacterium formerly known as H aegyptius belongs to the H influenzae species. It causes conjunctivitis and a fulminant invasive disease called Brazilian purpuric fever, called so because it was observed in Brazil in children aged 1-4 years who presented with high fever, vomiting, abdominal pain, petechiae, purpura, peripheral necrosis, and vascular collapse. Mortality may be as high as 70%.
  BIBLIOGRAPHY Section 10 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

  • American Academy of Pediatrics Committee on Infectious Diseases: Recommended childhood and adolescent immunization schedule: United States, 2005. Pediatrics 2005 Jan; 115(1): 182[Medline].
  • American Academy of Pediatrics: American Academy of Pediatrics. Haemophilus infulenzae infections. Red Book 2006: The Report of the Committee on Infectious Disease 2006; 27th ed: 310-318, 89.
  • Andrade AL, Martelli CM: Globalisation of Hib vaccination--how far are we? Lancet 2005 Jan 1-7; 365(9453): 5-7[Medline].
  • Bozdogan B, Appelbaum PC: Macrolide resistance in Streptococci and Haemophilus influenzae. Clin Lab Med 2004 Jun; 24(2): 455-75[Medline].
  • Centers for Disease Control and Prevention: Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002 Mar 22; 51(11): 234-7[Medline].
  • Claesson BA, Trollfors B, Lagergard T, et al: Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J 2005 May; 24(5): 463-4[Medline].
  • Daum R: Haemophilus influenzae. In: Behrman RE, Kliegman R, eds. Nelson Textbook of Pediatrics. 16th ed. Philadelphia, Pa: WB Saunders and Co; 2000: 833-837.
  • Daza P, Banda R, Misoya K: The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006 Sep 11; 24(37-39): 6232-9[Medline].
  • de Gans J, van de Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002 Nov 14; 347(20): 1549-56[Medline].
  • Fickweiler K, Borte M, Fasshauer M, et al: Meningitis due to Haemophilus influenzae type f in an 8-year-old girl with congenital humoral immunodeficiency. Infection 2004 Apr; 32(2): 112-5[Medline].
  • Gallaher TK, Wu S, Webster P: Identification of biofilm proteins in non-typeable Haemophilus Influenzae. BMC Microbiol 2006; 6: 65[Medline].
  • Garner D, Weston V: Effectiveness of vaccination for Haemophilus influenzae type b. Lancet 2003 Feb 1; 361(9355): 395-6[Medline].
  • Gessner BD, Sutanto A, Linehan M, et al: Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005 Jan 1-7; 365(9453): 43-52[Medline].
  • Gold R: Epidemiology of bacterial meningitis. Infect Dis Clin North Am 1999 Sep; 13(3): 515-25, v[Medline].
  • Hall-Stoodley L, Hu FZ, Gieseke A: Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006 Jul 12; 296(2): 202-11[Medline].
  • Kelly DF, Moxon ER, Pollard AJ: Haemophilus influenzae type b conjugate vaccines. Immunology 2004 Oct; 113(2): 163-74[Medline].
  • Leibovitz E, Jacobs MR, Dagan R: Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004 Dec; 23(12): 1142-52[Medline].
  • McIntyre PB, Berkey CS, King SM, et al: Dexamethasone as adjunctive therapy in bacterial meningitis. A meta- analysis of randomized clinical trials since 1988. JAMA 1997 Sep 17; 278(11): 925-31[Medline].
  • McVernon J, Trotter CL, Slack MP, Ramsay ME: Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004 Sep 18; 329(7467): 655-8[Medline].
  • Mitchell V, Walker D, Zuber P, et al: Evidenced-based decision making about Hib vaccination. Lancet 2005 Mar 12-18; 365(9463): 936-7[Medline].
  • Moxon ER, Murphy TF: Haemophilus influenzae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th ed. New York, NY: Churchill Livingstone; 2000: 2369-2378.
  • Murphy TF, Kasper DT: Infections due to Haemophilus influenzae, other Haemophilus species, the HACEK group, and other gram-negative bacilli. In: Braunwald E, Fauci AS, eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998: 924-928.
  • Peltola H, Salo E, Saxen H: Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data. BMJ 2005 Jan 1; 330(7481): 18-9[Medline].
  • Scheifele D, Halperin S, Law B, et al: Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. CMAJ 2005 Jan 4; 172(1): 53-6[Medline].
  • Starner TD, Zhang N, Kim G: Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 2006 Jul 15; 174(2): 213-20[Medline].
  • Steinhoff M, Goldblatt D: Conjugate Hib vaccines. Lancet 2003 Feb 1; 361(9355): 360-1[Medline].
  • Strausbaugh LJ: Haemophilus influenzae infections in adults: a pathogen in search of respect. Postgrad Med 1997 Feb; 101(2): 191-2, 195-6, 199-200[Medline].
  • Ward JI, Kenneth MZ: Haemophilus influenzae. In: Feigin RD, Cherry JD, Fletcher J, eds. Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia, Pa: WB Saunders and Co; 1998: 1464-1482.

Haemophilus Influenzae Infections excerpt